Table 8.
Surface under the cumulative ranking curve (SUCRA) and treatment ranking.
| SBP | DBP | ||||||
|---|---|---|---|---|---|---|---|
| Antihypertensive Regimens | SUCRA | Antihypertensive Regimens | SUCRA | ||||
| ARB + CCB | 9.396 | ARB + CCB | 0.9716 | ||||
| ARB + TZD | 0.8824 | ARB + TZD | 0.8468 | ||||
| ARB | 0.5565 | ARB | 0.6522 | ||||
| ACEI + CCB | 0.4810 | ARB + ACEI | 0.4594 | ||||
| ARB + ACEI | 0.3681 | ACEI | 0.2754 | ||||
| ACEI | 0.1615 | ACEI + CCB | 0.2441 | ||||
| CCB | 0.1109 | CCB | 0.0516 | ||||
| Major CVD | Hyperkalemia | ESRD | Death | ||||
|---|---|---|---|---|---|---|---|
| Antihypertensive Regimens | SUCRA | Antihypertensive Regimens | SUCRA | Antihypertensive Regimens | SUCRA | Antihypertensive Regimens | SUCRA |
| CCB + TZD | 0.8135 | CCB | 0.8909 | ACEI + CCB | 0.8082 | ARB + RI | 0.8515 |
| CCB | 0.7938 | CCB + BB | 0.6752 | ACEI + TZD | 0.6876 | ACEI | 0.6268 |
| CCB + BB | 0.7924 | CCB + TZD | 0.6604 | CCB | 0.5115 | ARB + ACEI | 0.5910 |
| ARB + CCB | 0.7730 | ACEI | 0.6080 | ARB | 0.4724 | ARB + CCB | 0.5242 |
| ARB | 0.4530 | ARB + RI | 0.5256 | ARB + CCB | 0.4616 | ARB | 0.5180 |
| ACEI + CCB | 0.4485 | ACEI + CCB | 0.4973 | ARB + ACEI | 0.4304 | ACEI + CCB | 0.4867 |
| ACEI + TZD | 0.3664 | ACEI + TZD | 0.4744 | ACEI | 0.3201 | CCB + BB | 0.4537 |
| ARB + RI | 0.3653 | ARB | 0.4559 | ARB + RI | 0.3082 | ACEI + TZD | 0.3981 |
| ACEI | 0.3418 | ARB + ACEI | 0.4146 | CCB + TZD | 0.3578 | ||
| ARB + ACEI | 0.3135 | ARB + CCB | 0.1637 | CCB | 0.1923 | ||
| ACEI + SPR | 0.0387 | ACEI + SPR | 0.1341 | ||||
Bolded antihypertensive treatment regimen indicates the reference of the network meta-analysis. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers; BB, beta-blockers; CCB, calcium channel blockers; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; ESRD, end-stage renal disease; RI, renin inhibitor; SBP, systolic blood pressure; TZD, thiazide diuretics; SPR, spironolactone.